NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post‑transplant lymphoproliferative disorder caused by the Epstein‑Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance